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Abstract
Prostate cancer cell lines provide ideal in vitro systems for the identification and analysis of prostate tumor sup-
pressors and oncogenes. A detailed characterization of the architecture of prostate cancer cell line genomes
would facilitate the study of precise roles of various genes in prostate tumorigenesis in general. To contribute
to such a characterization, we used the GeneChip 500K single nucleotide polymorphic (SNP) array for analysis
of genotypes and relative DNA copy number changes across the genome of 11 cell lines derived from both normal
and cancerous prostate tissues. For comparison purposes, we also examined the alterations observed in the cell
lines in tumor/normal pairs of clinical samples from 72 patients. Along with genome-wide maps of DNA copy num-
ber changes and loss of heterozygosity for these cell lines, we report previously unreported homozygous deletions
and recurrent amplifications in prostate cancers in this study. The homozygous deletions affected a number of
biologically important genes, including PPP2R2A and BNIP3L identified in this study and CDKN2A/CDKN2B re-
ported previously. Although most amplified genomic regions tended to be large, amplifications at 8q24.21 were
of particular interest because the affected regions are relatively small, are found in multiple cell lines, are located
near MYC, an oncogene strongly implicated in prostate tumorigenesis, and are known to harbor SNPs that are
associated with inherited susceptibility for prostate cancer. The genomic alterations revealed in this study provide
an important catalog of positional information relevant to efforts aimed at deciphering the molecular genetic basis
of prostate cancer.
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Introduction
Prostate cancer (PCa) cell lines have been widely used not only as
homogeneous tumor genomes for the identification of genetic alter-
ations including deletion, amplification, translocation, and single
nucleotide mutation but also as in vitro systems for studying the ex-
pression and function of various candidate tumor suppressor genes
(TSGs) and oncogenes. To fully evaluate the expression and/or func-
tion of a specific (group of ) gene(s) in a tumor genome, it is impor-
tant to know the relative status of the overall genetic integrity across
the genome because most genes and gene products interact with
others to impose a biologic effect resulting in a specific phenotype.
Various cytogenetic methods, including G-banding, spectral karyotyp-
ing and fluorescent in situ hybridization (FISH), and comparative ge-
nomic hybridization (CGH) such as metaphase (or conventional) and
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BAC/oligo/cDNA/single nucleotide polymorphic (SNP; or array-
based) hybridization, have been used in the characterization of various
PCa cell lines, primary and metastatic tumors, resulting in the identi-
fication of a number of recurrent losses and gains in the PCa tumor
genome [1–11].
Some losses and/or gains of genomic DNA may result from a gen-
eralized genomic instability combined with long-term culture and
associated proliferation of cancer cell lines and may not reflect altera-
tions of genes “driving” the cancer initiation and progression process.
However, a number of TSGs and oncogenes, such as PTEN and
MYC, have been identified through the analysis of deletion and am-
plification of genetic material in tumor genomes and have been ver-
ified through the functional analysis of the genes in appropriate cell
lines or in animal model systems.
Although single-copy losses and one– to two–extra-copy gains of
DNA are common, complete genetic loss of both alleles and more
extensive amplification of specific DNA sequences have been only
rarely observed in PCa. This may be, in part, due to the limited res-
olution of the methods used in the identification of these copy num-
ber alterations. Using cDNA array CGH with a resolution ∼570 kb,
Clark et al. [5] identified two novel regions of complete loss at
17q21.31 and 10q23.1 in the PC3 cell line. The sizes of homozy-
gous deletions in general are much smaller than typical hemizygous
deletions affecting only one allele, presumably due to the fatal effect
of large homozygous losses on the survival of the cancer cells. There-
fore, analysis of these homozygous deletions can make a more direct
contribution to the discovery of new genes involved in tumorigene-
sis. As the resolution of these analyses increases, additional homozy-
gous deletions of novel TSG are expected to be revealed.
Analyzing loss of heterozygosity (LOH) in the cancer genome has also
contributed to the identification of TSGs. Loss of heterozygosity due
to hemizygous deletion may or may not be accompanied by duplication
of the remaining allele. An analysis of both copy number changes and
genotyping to determine allele-specific alterations is necessary to dif-
ferentiate these possibilities. Although a number of CGH platforms
with various resolutions have been used for mapping most DNA copy
number alterations in the genome of PCa cell lines, SNP array is cur-
rently the only whole-genome approach for simultaneously mapping
copy number alteration and LOH in a single analysis. To date, this
type of high-resolution SNP arrays has not been used to analyze DNA
copy number changes and LOH simultaneously for prostate cell lines.
In addition to the deletion of TSGs and gain of oncogenes, gene
fusion events between androgen-regulated genes and the ETS family
of oncogenes have been recently demonstrated in most PCa [12,13].
These fusions result from balanced and more commonly nonbalanced
genetic translocations and deletions [13,14]. Using a combined cy-
togenetic and tiling array BAC CGH with a resolution of ∼78 kb,
Watson et al. [10] have demonstrated that a majority of balanced trans-
locations are actually imperfectly balanced and are associated with focal
deletions and duplications in PCa cell lines. Therefore, mapping the
breakpoints of these translocations, which requires very high reso-
lution, can provide valuable information characterizing gene fusion
events in PCa [15].
In this study, we simultaneously analyzed DNA copy number al-
teration and LOH using the GeneChip 500K SNP array with an av-
erage resolution of ∼5.8 kb in 11 prostate cell lines. In this report, we
uncover some previously unreported homozygous deletions and am-
plifications with gains of three or more extra copies of DNA in PCa,
along with a comprehensive map of copy number alteration and
LOH and the related copy number data of more than 500K SNP
probes for each of the cell lines. These data provide important posi-
tional information relevant to efforts aimed at deciphering the under-
lying molecular pathogenesis of PCa.
Materials and Methods
Cell Lines and DNA Isolation
PrECs are nonimmortalized early-passage human normal prostate
epithelial cells maintained in serum-free defined medium (i.e., PrEC
complete media). The cell and medium were obtained from Lonza
Walkerville, Inc. (Walkerville, MD). The human DU145, LNCaP,
PC3, and VCaP PCa cell lines were purchased from American Type
Culture Collection (Manassas, VA). LNCaP is hypotetraploid,
whereas DU145, PC3, LAPC4, and VCaP are near-triploid cell lines
(American Type Culture Collection) [6]. BPH1 is a nontumorigenic,
SV-40-immortalized, human prostate epithelial cell line generously
provided by Simon Hayward [16]. CWR22Rv1 is derived from a
human prostatic carcinoma xenograft that was serially propagated
in mice after castration-induced regression and relapse of the paren-
tal, androgen-dependent CWR22 xenograft and was generously pro-
vided by Thomas G. Pretlow [17]. E006AA is a hypertriploid cell
line established from primary PCa cells from an African-American
patient, which demonstrates androgen-sensitive growth in culture;
it was generously provided by Shahriar Koochekpour [18]. 975E/
hTERT is a human telomerase reverse transcriptase–immortalized cell
line derived from normal prostate cells generated from a radical pros-
tatectomy (RP) specimen of a patient with a family history of PCa
[19]. All of the cell lines were cultured in the RPMI-1640 medium
with 10% fetal bovine serum or as previously described [19]. PC82
is a hormone-dependent transplantable tumor, which was maintained
by serial xenograft transplantation in nude mice [20]; it was generously
supplied by Fritz Schroeder [21]. We isolated genomic DNA using a
DNA isolation kit from Gentra (Qiagen, Valencia, CA).
Clinical Samples
The clinical samples used in this study include 67 primary tumors
and 5 lymph node metastases. All primary tumors were from PCa
patients undergoing RP for treatment of clinically localized disease
at Johns Hopkins Hospital. For the analysis of somatic DNA copy
number alterations in these tumors, we selected cases from which ge-
nomic DNA of sufficient quantity (>5 μg) and purity (>70% cancer
cells for cancer specimens; no detectable cancer cells for normal sam-
ples) could be obtained by macrodissection of matched nonmalig-
nant (hereafter referred to as normal) and cancer-containing areas
of prostate tissue as determined by histologic evaluation of hematox-
ylin and eosin–stained frozen sections of snap-frozen RP specimens.
These include 9 with Gleason 6 tumors, 33 with Gleason 7 tumors,
6 with Gleason 8 tumors, 17 with Gleason 9 tumors, 1 with Gleason
10 tumors, and 1 having no Gleason score available.
GeneChip Mapping 500K SNP Assay
The GeneChipMapping 500K set comprised Nsp (∼262,000 SNPs)
and Sty (∼238,000 SNPs) arrays. The median physical distance be-
tween SNPs is ∼2.5 kb, and the average distance between SNPs is
∼5.8 kb. The 500K SNP arrays were purchased from Affymetrix,
Inc., Santa Clara, CA. All of the reagents used for the assay were ob-
tained from manufacturers recommended by Affymetrix. We labeled
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and hybridized the 500K SNP mapping arrays according to the man-
ufacturer’s instructions [15]. We washed and stained the arrays using
an Affymetrix Fluidics Station 450 and scanned the arrays using a
GeneChip Scanner 3000 7G (Affymetrix, Inc.). The genotype of each
SNP was generated by the GeneChip Genotyping analysis software
(GTYPE) of Affymetrix.
DNA Copy Number, LOH, and Classification of
Deletions and Gains
A database containing probe intensity and genotype data sets gen-
erated from the 500K SNP array using more than 200 DNA samples
from both blood and normal prostate cells was used as reference sam-
ples for DNA copy number analysis in the cell lines. Because the
ploidy levels vary among different cell lines, we normalized the data
of log2 ratio using most of the chromosomes as the baseline within
each of the tumor genomes based on the ploidy levels of the cell lines.
DNA copy number and LOH were calculated based on allele inten-
sity using two different software packages: Copy Number Analyzer
for Affymetrix GeneChip (CNAG2.0 [22]) and dChip analyzer
(dChip [23]). The physical positions of the detected deletions were
determined based on the Human hg17 Assembly (NCBI Build 35).
Deletions and gains are deduced from the average of log2 ratio with a
smoothing window of 10-SNP probes using CNAG2.0 and dChip.
The breakpoint SNPs were identified based on the median log2 ratio
with a smoothing window of five SNP probes.
To distinguish which allele is deleted or gained in the clinical sam-
ples, we used allele-specific analysis as described by Nannya et al.
[22]. The algorithm of allele-specific analysis takes advantage of ge-
notype information and allele-specific intensities from paired samples
to estimate DNA copy numbers for each heterozygous SNP. Allele-
specific analysis can also minimize the effect of normal DNA con-
tamination from nonmalignant cells in the tumors on the identifica-
tion of DNA copy number changes, because the probe intensity of
the other allele can be used as an internal reference for the detection
of hemizygous deletion or gain. When the allele intensities of the
match nontumor DNA are used as references, the homozygous de-
letion or gain can also be detected by allele-specific analysis.
We used the criteria described previously to define deletions and
gains [24]. Hemizygous deletion refers to the loss of one of the al-
leles, whereas homozygous (biallelic) deletion refers to the loss of both
alleles identified by allele-specific analysis in the clinical samples. In
cell lines, homozygous deletions were identified by CNAG2.0 with
a copy number of the probes equal to zero in default settings. The ab-
solute log2 ratios of one- and two-copy losses varied depending on the
ploidy levels of the cell lines but can be clearly distinguished according
to the criteria described previously [24]. For example, in near-triploid
cell lines, we used log2 ratios <−0.2 with an average of ∼−0.25 in
the 10-SNP genomic smoothed data to define one-copy loss, whereas
we used log2 ratios <−0.5 with an average of ∼−0.7 to define two-
copy loss and log2 ratios <−0.9 with an average of ∼−1.8 to define
three-copy (complete) loss. We used the same method to define gains.
For example, in near-triploid cell lines, we used log2 ratios >0.2 with
an average of ∼0.24 in the 10-SNP genomic smoothed data to define
one extra copy gain, whereas we used log2 ratios >0.4 with an average
of ∼0.6 to define two–extra-copy gain and >0.8 with an average of ∼1
to define three–extra-copy gain or more.Where the gains were three or
more extra copies, we define these gains as amplifications. We used
both quantitative polymerase chain reaction (PCR) and FISH data
to validate and refine the criteria for the copy number estimations.
Quantitative PCR
On the basis of the 500K SNP array analysis, we selected two nor-
mal DNA samples, PrEC from a primary culture of prostate epithelial
cells and 083 from the blood of an unaffected individual, as reference
samples for quantitative PCR (qPCR). The reaction was performed
using the ABI Prism 7500 Sequence Detection System (Foster City,
CA). Primers were designed using PrimerQuest software and were
synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).
Amplicons were designed against the putatively homozygous-deleted
and -amplified loci in the tumor cells and a control locus of known
normal DNA copy number. The sequences of the primers forBNIP3L,
PPP2R2A, CDKN2A, CDKN2B, RAB20, ING1, OTUB1, MARK1,
and a locus at 8q24.11 are available on request. Polymerase chain re-
action kinetics at the control locus with normal DNA copy number
was used to control for sample-to-sample differences in genomic
DNA purity and concentration. Polymerase chain reaction conditions
and determination of deletion and gain were described previously [15].
Fluorescent In Situ Hybridization
Fluorescent in situ hybridization was performed to analyze the
DNA copy number of the androgen receptor gene (AR) in E006AA
cells. CEP × (DX21) spectrum green probe (for centromere control)
and the AR (Xq12) spectrum orange probe were purchased from Vysis,
Inc. (Downers Grove, IL). Cell preparation and hybridization were
carried out according to the manufacturer’s protocol. Both interphase
and metaphase analyses were performed to estimate DNA copy num-
ber of AR in relationship to centromere in E006AA and cells from a
normal male as control. Fluorescent in situ hybridization analysis was
performed using fluorescent microscopy with the appropriate filters
to visualize the probes. Slides were blinded, then for each sample, a
total of 100 interphase nuclei were scored and a ratio of red signals
(AR) to green signals (Xcen) was calculated.
Results
Copy Number Alterations and LOH Revealed by the
500K SNP Array in PCa Cell Lines
DNA copy number alterations in each of the 11 genomes for each
chromosome are presented in Figures W1 to WX. The deletions and
gains are inferred from the 10-SNP genomic smoothed log2 ratios of
the hybridization intensity for each of the 500K probes analyzed (pre-
sented in a supplementary data set for each of the cell lines, http://
www1.wfubmc.edu/Genomics/Publications+and+Data). Among the
cell lines analyzed, PC3 and VCaP harbor the most DNA copy num-
ber alterations. Within these two cell lines, chromosome 5 harbors the
most changes (Figure W5). In contrast, there were no large DNA copy
number aberrations found in PrEC, although some small copy num-
ber variations were observed, for example, on chromosomes 14q and
15q (Figures W14 and W15, red arrows) in these presumably normal
prostate epithelial cells. We also documented deletions and gains in
prostate cell lines that had not been analyzed previously by array
CGH (e.g., 975E, E006AA, and PC82; Figures W1–WX).
Because the SNP array also generates genotypes at each of the
500K SNPs, it was possible to analyze LOH across the whole genome
for each of the cell lines using CNAG2.0 (FiguresW1–WX). As would
be predicted from similar previous studies, some regions of LOH
cover the entire chromosomes in some of the cell lines. These include
chromosomes 3, 7, 9, 13, and 14 in E006AA, chromosome 13 in
DU145, chromosomes 8, 9, 10, 16, and 22 in PC3, and chromosome
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18 in VCaP, reducing hundreds to thousands of genes to homozygos-
ity in these cell lines. Because some LOH events were not accompa-
nied by copy number changes, LOH in these instances apparently
occurred along with gain of the remaining chromosomal copy, either
completely or partially (Figure 1). In addition, we analyzed the mini-
mum common regions (MCRs) of recurrent LOH and listed the six
that occurred in at least four cell lines in Table 1. Among the many
genes affected by these recurrent alterations are known and suggested
TSGs such as TUSC1, PTEN, and KLF5 and genes involved in cel-
lular senescence (MORF4), DNA repair (HMGB2 and EPC1), and
oxidative stress (MGST1).
Homozygous Deletions Implicate New Genes Involved in
Prostate Cancer
We used three different approaches in the identification of homo-
zygous deletions, including the value of log2, SNP call (no call), and
qPCR. Although, in general, it is not feasible to use default settings
of CNAG2.0 to generate calls for a specific copy number alteration
(other than homozygous deletion with a copy number equal to zero)
in the presence of multiple levels of deletion in polyploid cells, there
are obvious differences in log2 ratios between levels of deletion within
a given genome when it is analyzed using the 500K SNP array. Tak-
ing the deletions on chromosome 5 in near-triploid cell lines PC3,
for example (Figure 2a), we were able to clearly identify one-copy
deletions (light blue arrows), two-copy deletions (black arrows), and
complete or homozygous deletions (green arrows). In the regions of
homozygous deletion, we found the no-call rate increased in compar-
ison to the regions without homozygous deletion, consistent with
loss of all copies of the specific genomic interval. To validate the ho-
mozygous deletion calls, we performed qPCR and confirmed the re-
sults as shown in Figure 2b.
Using the 500K SNParray, we identified 12 homozygous deletions in
five cell lines, with 7 apparently being novel (Figure 2, a and c). Half of
these deletions occurred in a single cell line, PC3. The genes affected
Table 1. Examples of Recurrent LOH Revealed by the 500K Mapping Array in Prostate Cancer Cell Lines.
Cell Line Chromosome Start End Size (bp) Gene
975E, CWR22Rv1, DU145, E006AA, PC3 4 171,890,559 176,165,998 4,275,439 AK128523, SAP30, GALNT7, HMGB2, SCRG1, MORF4, FBXO8, HPGD, GLRA3
DU145, E006AA, PC3, PC82 9 22,021,005 25,996,565 3,975,560 AF109294, DMRTA1, ELAVL2, TUSC1
BPH1, DU145, PC3, PC82 10 30,398,784 34,803,394 4,404,610 19 genes, MAP3K8, TCF8, EPC1
E006AA, LNCaP, PC3, PC82 10 88,889,330 90,573,072 1,683,742 11 genes, MINPP1, PTEN, LIPF
DU145, LAPC4, LNCaP, PC3 12 16,235,442 17,277,690 1,042,248 MGST1, LMO3
DU145, E006AA, LNCaP, PC82, VCaP 13 72,316,041 74,078,996 1,762,955 C13orf24, KLF5, KLF12
Figure 1. Examples of DNA copy number changes and LOH identified by CNAG2.0. Log2 ratios (horizontal dotted lines) are labeled for each of
the chromosomes on the left as 1, 0, and−1, with 0 being the baseline (light blue). Dark blue curve indicates 10-SNP genomic smoothed log2
ratios of Nsp probes. Blue bars superimposed on the yellow bars represent LOH likelihood with the likelihood gradients labeled on the left.
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by these novel homozygous deletions include CDH18, AK130123,
PPP2R2A, BNIP3L, MAT1A, LOC143241, AK125908, C10orf58,
BC005871, TSPAN14, SH2D4B, MAP4K5, SPG3A, SAV1, USP10,
CR593410, ZDHHC7, KIAA0513, FLJ44299, MGC22001, and
PPAP2C. The cyclin-dependent kinase inhibitors CDKN2A and
CDKN2B were found to be deleted in the E006AA line, the only line
in this study derived from PCa arising in an African-American. No-
tably, each homozygous deletion was unique in that it was observed
only once among the lines examined, although a subset of these de-
letions was observed additional times in the clinical specimens exam-
ined (see below). All of the homozygous deletions reside in larger
regions of LOH (Figures W2, W5, W6, W8, W9, W10, W14,
W16, W17, and W19). We confirmed five other regions that have
been reported to be completely lost: on chromosome 2 in LNCaP;
chromosomes 5, 10, and 17 in PC3; and on chromosome 6 in
DU145, including the genes MSH2, KIAA0416, PTEN, SFTPA2,
CTNNA1, STAT3, and STAT5B. Furthermore, using the 500K SNP
array, we defined boundaries of previously reported homozygous dele-
tions more closely and identified more affected genes, which include
KCNK12, LRRTM2, C10orf59, LIPL1, LIPF, LGP2, GCN5L2,
HSPB9, RAB5C, KCNH4, HCRT, AK075277, LGP1, STAT5B,
STAT5A, PTRF, and ATP6V0A1 (Figure 2c).
Screening for these homozygous deletions in the clinical samples
from 72 patients with PCa using allele-specific analysis, we found
five recurrent biallelic losses on chromosomes 8, 9, 10, and 16, with
examples shown in Figure 2d (green arrows). The most common com-
plete loss of both alleles occurred at chromosome 10q23.31 and in-
cluded PTEN, with a frequency of 21%, whereas the frequency of
homozygous deletions at 9p21.3 and 16q24.1 was 4.2% (Figure 2c).
The regions of complete loss at 9p21.3 in the clinical samples overlap
with that observed in cell line E006AA, with an MCR affecting only
CDKN2A and CDKN2B from 21,968 to 22,125 kb (Figure 2c). The
MCR of complete loss at 16q24.1 in the VCaP cell line and clinical
samples ranges from 83,300 to 83,541 kb, affecting the genes USP10
and CRISPLD2. We also observed single occurrences of homozygous
deletions on 8p in the 72 clinical samples. The complete loss at 8p21.2
in a primary tumor affected AK130123, EBF2, PPP2R2A, and
BNIP3L. We did not observe any complete losses at the other regions
listed in Figure 2c in the clinical samples analyzed.
Amplifications with More Than Two Extra Copies
Using the same approach as described above for the analysis of
multiple levels of deletion, we were able to define multiple levels
of gain, as shown in Figure 3. Taking the gains on chromosomes 1
(Figure 3a) and 10 (Figure 2a) in PC3, for example, we identified
gained regions with one, two, and three or more extra copies, marked
by brown, pink, and red arrows, respectively, in this near-triploid ge-
nome. In comparison to homozygous deletions (Figure 2, a and c),
the size of the amplifications, as defined by the presence of three or
more extra copies, and ranging from approximately 88 kb to 7.8 Mb,
was generally far larger than the homozygous deletions observed and
affected a number of genes in various cell lines (Figure 3b). To con-
firm these amplifications, we selected five different regions on chro-
mosomes 8, 11, and 13 and performed qPCR analysis of DNA copy
number using GAPDH as the control locus. For example, in VCaP as
shown Figure 4, the results of qPCR analysis revealed gains of mul-
tiple copies of RAB20, ING1, OTUB1, and MARK2. In addition, we
also validated the amplification of an amplicon at 8q24.21 where sev-
eral germ line PCa risk alleles have been identified in populations of
both European and African descent. Whereas most of the regions
with amplification were observed only once in this group of analyzed
cell lines, the amplification at 8q24.21 was found in 3 of these 11 cell
lines (Figure 3b).
Analyzing the gains in the 72 clinical samples, we did not find the
amplifications that we had observed in the cell lines shown in
Figure 3b, except at chromosome 8q (Figure 2d). Among these clin-
ical samples, approximately 38% harbor gains on 8q with most of
them being hemizygous and affecting the entire q arm. In the allele-
specific analysis, we identified three tumors harboring biallele gains,
ranging from 98,928 kb to 8qter (Figure 2d, red arrows), which over-
lap with the amplifications at 8q24. However, the MCR ranging
from 128,776 to 136,826 kb in the clinical samples is located 3′
from the MCR in the cell lines and affected a number of genes in-
cluding MYC.
In addition, we detected an amplification event on chromosome X,
ranging from 65,893 to 66,811 kb in VCaP. This alteration harbored
only the AR gene and was present in at least five extra copies (Figure 3).
Amplification of AR was also observed in the cell line E006AA,
although the affected region was larger, ranging from 64,829 to
76,599 kb, covering a number of genes (Figure WX). The gain of
AR in E006AA cells was confirmed by FISH where metaphase analysis
indicated two copies of the X centromere (Figure 4i, green), consistent
with the previously reported karyotype [18] and what seems to be two
to three or more copies of the AR gene per X chromosome (Figure 4i,
red ). Interphase analysis demonstrated multiple red signals in relation
to the number of green signals that could be more easily counted than
in the metaphase. The number of green signals per nucleus ranged
from 1 to 7 and the number of red signals per nucleus ranged from
3 to 18 (Figure 4h), indicating extensive genetic heterogeneity within
these cells. On average, we observed 5.5 copies of ARwith 2.2 copies of
CEP X signals per nucleus, which is consistent with the result from the
SNP array analysis (Figure WX). In comparison to E006AA, VCaP
apparently harbors a higher level of AR amplification, according to
the log2 ratios and metaphase analysis of FISH (Figure WX and data
not shown).
Discussion
Alterations of DNA copy number in prostate cell lines, such as
LNCaP, PC3, and DU145, have been systematically analyzed using
cDNA microarray [5,8] and BAC tiling path array CGH [10]. Al-
though the large-scale genomic alterations uncovered by various plat-
forms are very similar, we find that the deletions and gains revealed
by the 500K SNP array are more consistent with the results gener-
ated from the higher-resolution tiling path array than those from the
cDNA arrays, which contain fewer and less evenly distributed probes.
The varied results from study to study are most likely due to these
factors, although variations in the cell lines themselves cannot be ruled
out. Nevertheless, the comprehensive analysis and documentation of
DNA copy number changes in these widely used in vitro model sys-
tems provides a detailed genetic background for studying PCa biology.
One of the hallmarks of cancers is genomic instability resulting in
aneuploidy, which has been considered as a valuable predictor of clin-
ical outcome [25]. To more specifically characterize the aneuploidy in
PCa cell lines, we took advantage of the genotype data from the
500K SNP array and analyzed LOH across the entire genome using
CNAG2.0. We found that some entire chromosomes or arms lost het-
erozygosity, although the DNA copy number either did not change
or increased. This type of LOH apparently resulted from the loss of
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one chromosome or arm in combination with the amplification of the
other chromosome or arm. It would be interesting to explore the bio-
logic impact in processes, such as progression of PCa, of large LOH
events resulting in the reduction to homozygosity of many hundreds
to thousands of genes, with or without accompanying further changes
through deletion and gain.
Complete losses of DNA at five chromosomal regions have been
reported in PC3 and DU145 [5]. We have validated three of these
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regions on chromosomes of 5, 10, and 17. It is not surprising that
the most frequent homozygous deletion in these 72 clinical samples
analyzed in this study was found at 10q23.31, affecting PTEN.
These results emphasize the significance of losing PTEN in the de-
velopment of PCa. Somewhat surprisingly, occurrences of deletions
between the TMPRSS2 and ERG genes were less common in these
cancer cell lines (Figure W21), particularly considering the high fre-
quency of these deletions in clinical samples of prostate cancer, al-
though the number of the cancer cell lines analyzed is too small to
be conclusive. This may suggest a counterselection for this genomic
alteration in PCa cells, which can grow and can be established in cul-
ture. Furthermore, these results emphasize some of the different se-
lection pressures that exist for PCa cells in patients versus in culture.
Although these cell lines are valuable models to study human PCa in
general, some critical differences should be borne in mind when ex-
trapolating results from in vitro to in vivo settings.
Particularly interesting genes affected by complete losses identified
in PCa cell lines and the clinical samples in this study include BNIP3L
and PPP2R2A at 8p21.2, CDKN2A and CDKN2B at 9p21.3, USP10
and CRISPLD2 at 16q24.1, and MAP4K5 at 14q21.3. BNIP3L
(BCL2/adenovirus E1B 19-kDa interacting protein) encodes a protein
that is a functional homolog of BNIP3 and may play a role in tumor
suppression [26]. Fei et al. [27] found that the expression of BNIP3L
was induced by p53 under hypoxia, and its knockdown promoted
tumor growth in vivo. Down-regulation of BNIP3L has been reported
to be correlated with liver metastases and tumor invasion [28] and
Figure 2. (continued)
Figure 2. Homozygous deletions identified in PCa cell lines. (a) Log2 ratios (horizontal dot lines) are labeled for each of the chromosomes
on the left as 1, 0, and −1, with 0 being the baseline (light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of the
500K probes. Green arrows indicate homozygous deletion. Red arrow indicates amplifications with three or more extra copies. Light
blue arrow indicates one-copy loss. Black arrow indicates two-copy loss. Brown arrow indicates one–extra-copy gain. Pink arrow indi-
cates two–extra-copy gain. (b) Validation of homozygous deletions in PCa cell lines using qPCR. The raw signal intensities for each of the
test loci were normalized against the signal intensity of control locus (GAPDH) with normal copy numbers for each of the cycles. The
normalized relative signal intensities (Y-axis) are plotted for each of the PCR cycles (X-axis), with 083 from normal blood DNA used as a
reference. No signals of PPP2R2A and BNIP3 detected in VCaP indicate complete loss of these two genes. (c) Physical locations and
genes involved in homozygous deletions. Chr indicates chromosome; P tumor, clinical sample. (d) Examples of recurrent homozygous
deletions (green arrows) and biallelic gains (red arrows) identified in different clinical samples by allele-specific analysis. Log2 ratios of
the two alleles (red and green curves) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). G6, G7, G8, and G9 represent Gleason scores of 6, 7, 8, and 9, respectively, for different subjects.
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poor prognosis in hepatocellular carcinoma [29]. PPP2R2A belongs
to the phosphatase 2 regulatory subunit B family. Protein phosphatase
2 is one of the four major Ser/Thr phosphatases and is implicated
in the negative control of cell growth and division. Studying the fusion
of CHEK2 and PPP2R2A in childhood teratoma, Jin et al. [30] re-
ported that the deregulation of CHEK2 and/or PPP2R2A is of patho-
genetic importance in at least a subset of germ cell tumors. CDKN2A
and CDKN2B are cyclin-dependent kinase inhibitors. CDKN2A,
also named as multiple tumor suppressor (MTS1), encodes p16INK4a
and p14ARF and acts as a negative regulator of the proliferation of
normal cells by interacting strongly with CDK4 and CDK6. De-
fect in CDKN2A is involved in tumor formation in a wide range of
tissues and is the cause of familial atypical multiple mole melanoma–
pancreatic carcinoma syndrome. Although hemizygous deletion of
Figure 3. Examples of amplifications with three or more extra copies identified in PCa cell lines. (a) Log2 ratios (horizontal dot lines) are
labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline (light blue). Red arrow indicates amplification
with three or more extra copies. Brown arrow indicates one–extra-copy gain. Pink arrow indicates two–extra-copy gain. (b) Physical
locations and genes involved in amplification. An asterisk (*) represents a known gene item count from the UCSC Table Browser utility
(University of California, Santa Cruz, CA).
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CDKN2A has been reported in prostate tumors [31–33], homozy-
gous deletion of this gene in prostate tumors and cancer cell lines
was not observed in several studies [33–35]. However, homozygous
deletion of CDKN2A has been observed at low frequency in prostate
tumors with a high Gleason score [36]. CDKN2B lies adjacent to the
TSG CDKN2A. Using a systematic multiplex reverse transcription–
polymerase chain reaction, Yamamoto et al. [37] found a decrease in
expression of this gene in most breast and PCa cell lines. USP10 may
function as a cofactor of the DNA-bound androgen receptor complex
and is inhibited by a protein in the Ras–GTPase pathway, whereas
CRISPLD2 seems to be highly expressed in prostate.MAP4K5 encodes
a member of the serine/threonine protein kinase, which was shown
to activate Jun kinase in mammalian cells, suggesting a role in stress
response. This kinase is expressed at high levels in the ovary, testis,
and prostate, whereas expression is decreased in PCa (ONCOMINE,
http://www.oncomine.org/).
Most of the regions with amplification were large, affected a number
of genes, and like homozygous deletions, were observed only once in
this group of prostate cell lines. It is therefore hard to draw a connec-
tion between these amplifications and tumorigenesis because of the
large number of genes affected and because most of the affected genes
have little obvious relevance to the development of PCa on the basis
the functional descriptions in public databases. However, the ampli-
fication at 8q24.21 was very interesting because it was found in
two PCa cell lines and was located nearMYC, an oncogene that is fre-
quently up-regulated in a number of cancers. It is of particular interest
Figure 4. Validation of amplifications in PCa cell lines using qPCR and FISH. Amplifications of RAB20 (a), OTUB1 (b), ING1 (d),MARK2 (e),
and a locus at 8q24 (c and f) confirmed by qPCR. Cycle numbers (C t) of the control (GAPDH; X-axis) with normal copy number and test
amplicons (Y-axis) for the three dilutions of eachDNA samplewere plotted against each other and the offset between the reference sample
(083–003; blue) and DNA from cell lines (red). Fluorescent in situ hybridization analysis of DNA copy number of AR in a normal male control
cell line (g) and in the PCa cell line E006AA (h and i). Green indicates the X centromere probe. Red indicates the AR probe at Xq12. Meta-
phase analysis of E006AA indicated two copies of X centromere (green) and what seem to be multiple copies of the AR gene (red).
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that the gained region harbors a number of risk variants, including
rs10086908, rs16901979, rs6983267, rs10505477, rs7017300, and
rs1447295, which are associated with both prostate and colorectal
cancer susceptibility in various human populations [38,39]. This am-
plification was also observed in BPH1, a nontumorigenic prostate ep-
ithelial cell line, indicating that the occurrence of this amplification
event by itself is not sufficient for tumorigenesis. Further study is war-
ranted to dissect the function of these DNA sequences in regulating
the development of PCa.
The other recurring region of amplification was observed at Xq12,
occurring in two of the PCa cell lines analyzed. In both cases, the AR
gene was included in the amplified region, either alone or in combi-
nation with several other genes. It is well established that the andro-
gen receptor plays a key role in the progression of PCa to hormone
independence. A highly localized amplification of AR was apparently
associated with the androgen-deprived selection of the PCa cells in
the vertebral metastatic deposit from which the VCaP cell line was
derived [40]. However, AR amplification was also observed in
E006AA that was derived from a clinically localized primary prostate
cancer from an African-American patient that apparently had not un-
dergone hormone deprivation treatment. Whether the gain of AR se-
quences occurred before or after establishment of the E006AA cells
in culture is unclear. In any case, these results emphasize that gain of
AR sequences is a recurring but by no means a mandatory event as-
sociated with prostate cancer progression.
In summary, while documenting DNA copy number changes and
LOH at >500,000 locations across the entire genome of 11 prostate
cell lines, we have highlighted the following: 1) unreported LOH re-
gions, including frequent monosomy with accompanying gain and
loss, 2) novel homozygous deletions that implicate new genes in-
volved in PCa, 3) gains of AR in two cell lines, and 4) recurrent am-
plification of regions that harbor a number of germ line risk SNPs
that have been identified in both prostate and colorectal cancers. Fur-
ther studies are needed to evaluate whether risk SNPs in the germ
line play any role in the amplification of chromosome 8q including
the oncogene MYC, and ultimately whether amplification of these
SNPs in the somatic genome contributes to the formation of PCa.
Deletion and gain of a number of regions that affect numerous
genes in the tumor genomes of PCa have been identified [41]. How-
ever, only a few these genes have been investigated in the functional
analyses using in vitro and in vivo systems with limited knowledge on
their genomic architectures. In this study, we provide the genomic
architectures of 11 prostate cell lines at high resolution, which will
facilitate further functional analysis of a number of candidate TSGs
and oncogenes, including the novel ones identified in this study.
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Figure W1. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W2. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W3. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W4. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W5. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W6. Maps of DNA copy number alterations and LOH generated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed log2 ratios of Nsp probes. Blue bars superimposed on the yellow bars
represent LOH likelihood with the gradients as shown in Figure 1. Red arrows indicate DNA copy number variations.
Figure W7. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and−1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W8. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and−1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W9. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and−1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W10.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W11. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W12.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W13.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W14.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W15. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W16.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W17.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W18.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W19. Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W20.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W21.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure W22.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and −1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
Figure WX.Maps of DNA copy number alterations and LOH gener-
ated by CNAG2.0 for chromosomes 1 (W1) to X (WX) in prostate cell
lines. Log2 ratios (horizontal dotted lines) are labeled for each of the
chromosomes on the left as 1, 0, and−1, with 0 being the baseline
(light blue). Dark blue curve indicates 10-SNP genomic smoothed
log2 ratios of Nsp probes. Blue bars superimposed on the yellow
bars represent LOH likelihood with the gradients as shown in Fig-
ure 1. Red arrows indicate DNA copy number variations.
